CVM: CEL-SCI Corporation Net earnings per share (EPS TTM)
CEL-SCI Corporation revenues are based on finding a capital balance during the period of drug clinical trials. The TTM net income per share illustrates the quality of the business, where the metric value is -2.60. Growth prospects rely on the implementation of biologics in surgery and compliance with environmental standards for chemical waste processing in research centers.
cel-sci.com - analytical breakdowns and key metrics (CVM)
- current quotes and average value forecast:
- market capitalization information:
- business book valuation details:
- debt and liquidity details:
- net income and valuation multiples indicators:
CVM - Net Financial Result|Future Profit CEL-SCI Corporation|CVM - Company Value to Net Income|Forward P/E Multiple CEL-SCI|CVM - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CEL-SCI Corporation|CVM - Profit before interest, taxes and amortization|Earnings per share for the last twelve months CEL-SCI|CVM - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months cel-sci.com|CVM - Earnings per share trend in current year|Net earnings per share growth forecast for next year CEL-SCI Corporation
- revenue and sales details:
Comprehensive company analysis:CVM - CEL-SCI Corporation
CEL-SCI Corporation (CVM) operates in an intensive R&D mode without commercial sales, leading to a systemic reduction of capital. Fundamental net income per share TTM aggregates annual results, distributing the final financial outcome across the total volume of issuance. Negative dynamics for this metric reflect the burn rate of resources dedicated to immunotherapy development. This chart allows for an assessment of the business's loss rates. Investors perceive this trend as a risk of liquidity depletion.
Competitors of CEL-SCI Corporation
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Biosciences, Inc.)|CADL: Net earnings per share (EPS TTM)|Accuray Inc (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group|Net earnings per share (EPS TTM) Actuate Therapeutics, Inc.|Earnings per share for the last twelve months citiusonc.com (CTOR)|Net earnings per share (EPS TTM) TuHURA (HURA)|Net earnings per share (EPS TTM) TARA (protaratx.com)|Earnings per share for the trailing year FATE|WHWK - Earnings per share for the last twelve months|Earnings per share for the trailing year TCRX (tscan.com)|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|OSTX (OS Therapies Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Radiopharm Theranostics (RADX)|Net earnings per share for the last 12 months ARTV (Artiva Biotherapeutics, Inc.)|ANL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Veru Inc. VERU|Earnings per share for the trailing year TPST|XLO: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Renovaro RENB|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Kairos Pharma Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months OKUR|Net earnings per one share for the last twelve months CytoMed Therapeutics Limited GDTC|Net earnings per share (EPS TTM) CRIS|Net earnings per share (EPS TTM) Apollomics Inc. (APLM)|Net earnings per share (EPS TTM) THAR (Tharimmune Corp)|Net earnings per share for the last four quarters Advanced Biomed Inc (ADVB)|Genprex Inc - Net earnings per share (EPS TTM)|CLDI - Net earnings per share (EPS TTM)|Sunshine Biopharma Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
